Takefumi Yoshida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Takefumi Yoshida has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Yoshito Akagi
Kurume University of Medicine
10 shared publications- Tetsushi Kinugasa
Kurume University
9 shared publications - Kazuo Shirouzu
Department of Surgery, Kurume University School of Medicine, Fukuoka, Japan
8 shared publications Yasuhiko Ryu
6 shared publicationsYukito Gotanda
Department of Surgery, Kurume University School of Medicine, Fukuoka, Japan
4 shared publicationsKansakar Romeo
3 shared publications
Latest Publications
- Open Access
- 29 October 2021
- Published by Springer Nature in Research Square
Examination of main lymph node (No.253) metastasis in left colorectal cancer: A retrospective analysis of a single-institution cohort
Background. The extent of lymph node dissection in advanced colorectal cancer varies according to regional guidelines. D3 lymphadenectomy is routinely performed in Japan but is associated with several risk factors. Metastases of the main lymph nodes (No.253 lymph nodes), which are located at the root of the inferior mesenteric artery, are rare in left-sided colorectal cancer. Tumor depth (T4) is an identifier of No.253 lymph node metastasis (LNM) risk, but other risk factors associated with No.253 LNM are unclear. This study was undertaken to investigate the frequency of No.253 LNM and to identify other clinicopathological risk factors associated with No.253 LNM in left-sided colorectal cancer. In this study, we aimed to evaluate the clinical benefit of routine D3 lymphadenectomy in surgically treated advanced colorectal cancer. Methods. A retrospective database of patients with colorectal cancer who underwent D3 dissection and R0 resection at Kurume University Hospital from 1978 to 2017 was constructed and used to search for the frequency and risk factors of No.253 LNM to investigate long-term prognosis. Clinicopathological factors associated with No.253 LNM, including age, sex, tumor location, T stage, tumor diameter, carcinoembryonic antigen levels, and various dissected lymph nodes, were analyzed. Results. Among 1,614 consecutive patients, No.253 LNM was observed in 23 cases (1.4%). The presence of three or more regional LNMs was an independent risk factor for No.253 LNM (odds ratio: 26.8). The 5-year overall survival rate was 49.1% in the No.253 LNM-positive group and 78.4% in the No.253 LNM-negative group (p=0.002). Conclusion. In left-sided colorectal cancer, No.253 LNM was a poor prognosis factor, and three or more regional LNMs were a risk factor for No.253 LNM. The No.253 LNM-positive group had a poor prognosis, but there are cases of long-term survival, with a 5-year survival rate of 49%. D3 lymphadenectomy is suitable when three or more metastatic LNs are identified prior to surgery.
- 29 October 2021
- Published by Springer Nature in Research Square
Open AccessExamination of main lymph node (No.253) metastasis in left colorectal cancer: A retrospective analysis of a single-institution cohort
Background. The extent of lymph node dissection in advanced colorectal cancer varies according to regional guidelines. D3 lymphadenectomy is routinely performed in Japan but is associated with several risk factors. Metastases of the main lymph nodes (No.253 lymph nodes), which are located at the root of the inferior mesenteric artery, are rare in left-sided colorectal cancer. Tumor depth (T4) is an identifier of No.253 lymph node metastasis (LNM) risk, but other risk factors associated with No.253 LNM are unclear. This study was undertaken to investigate the frequency of No.253 LNM and to identify other clinicopathological risk factors associated with No.253 LNM in left-sided colorectal cancer. In this study, we aimed to evaluate the clinical benefit of routine D3 lymphadenectomy in surgically treated advanced colorectal cancer. Methods. A retrospective database of patients with colorectal cancer who underwent D3 dissection and R0 resection at Kurume University Hospital from 1978 to 2017 was constructed and used to search for the frequency and risk factors of No.253 LNM to investigate long-term prognosis. Clinicopathological factors associated with No.253 LNM, including age, sex, tumor location, T stage, tumor diameter, carcinoembryonic antigen levels, and various dissected lymph nodes, were analyzed. Results. Among 1,614 consecutive patients, No.253 LNM was observed in 23 cases (1.4%). The presence of three or more regional LNMs was an independent risk factor for No.253 LNM (odds ratio: 26.8). The 5-year overall survival rate was 49.1% in the No.253 LNM-positive group and 78.4% in the No.253 LNM-negative group (p=0.002). Conclusion. In left-sided colorectal cancer, No.253 LNM was a poor prognosis factor, and three or more regional LNMs were a risk factor for No.253 LNM. The No.253 LNM-positive group had a poor prognosis, but there are cases of long-term survival, with a 5-year survival rate of 49%. D3 lymphadenectomy is suitable when three or more metastatic LNs are identified prior to surgery.
- 9 August 2019
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 26 (S3) , 686-687
ASO Author Reflections: Partial versus Total Cystectomy in Bladder-Involving Colorectal Cancer
- 9 August 2019
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 26 (S3) , 686-687
ASO Author Reflections: Partial versus Total Cystectomy in Bladder-Involving Colorectal Cancer
- 7 March 2019
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 26 (5) , 1569-1576
Long-Term Outcomes Following Partial Versus Complete Cystectomy in Advanced Colorectal Cancer with Regarding to the Extent of Bladder Invasion
Background Two procedures widely performed to treat locally advanced colorectal cancer adherent to the urinary bladder are total cystectomy (as part of pelvic exenteration) and partial cystectomy;...
- 7 March 2019
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 26 (5) , 1569-1576
Long-Term Outcomes Following Partial Versus Complete Cystectomy in Advanced Colorectal Cancer with Regarding to the Extent of Bladder Invasion
Background Two procedures widely performed to treat locally advanced colorectal cancer adherent to the urinary bladder are total cystectomy (as part of pelvic exenteration) and partial cystectomy;...
- Open Access
- 29 December 2014
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 470
Bowel obstruction caused by an internal hernia that developed after laparoscopic subtotal colectomy: a case report
Laparoscopic surgery is a minimally invasive approach with good treatment outcomes and is currently the standard surgery for colorectal cancer in Japan. Mesenteric closure is considered unnecessary in laparoscopic colorectal surgery because it can damage the bowel and blood vessels. However, an internal hernia may develop if the mesentery is not repaired. We report a case of internal hernia in a 61-year-old male of Japanese ethnicity. The patient had advanced sigmoid colon cancer, early-stage transverse colon cancer, and multiple adenomatous polyposis, and underwent laparoscopically-assisted subtotal colectomy. Bowel obstruction developed six days postoperatively and did not improve with conservative treatment. Abdominal computed tomography detected an internal hernia, prompting emergency surgery in which the ileum protruding into the mesenteric defect and an anastomotic stricture were detected. Reanastomosis, mesentery closure, and ileostomy were performed after hernia repair. In this case, open surgery was necessary due to bowel obstruction after laparoscopic colectomy. This outcome indicated that mesenteric closure should have been performed. Thus, the benefits of mesenteric closure require assessment in future cases.
- 29 December 2014
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 470
Open AccessBowel obstruction caused by an internal hernia that developed after laparoscopic subtotal colectomy: a case report
Laparoscopic surgery is a minimally invasive approach with good treatment outcomes and is currently the standard surgery for colorectal cancer in Japan. Mesenteric closure is considered unnecessary in laparoscopic colorectal surgery because it can damage the bowel and blood vessels. However, an internal hernia may develop if the mesentery is not repaired. We report a case of internal hernia in a 61-year-old male of Japanese ethnicity. The patient had advanced sigmoid colon cancer, early-stage transverse colon cancer, and multiple adenomatous polyposis, and underwent laparoscopically-assisted subtotal colectomy. Bowel obstruction developed six days postoperatively and did not improve with conservative treatment. Abdominal computed tomography detected an internal hernia, prompting emergency surgery in which the ileum protruding into the mesenteric defect and an anastomotic stricture were detected. Reanastomosis, mesentery closure, and ileostomy were performed after hernia repair. In this case, open surgery was necessary due to bowel obstruction after laparoscopic colectomy. This outcome indicated that mesenteric closure should have been performed. Thus, the benefits of mesenteric closure require assessment in future cases.
- 1 August 2014
- Vol. 34 (8) , 4569-75
Minichromosome maintenance protein 7 is a risk factor for recurrence in patients with Dukes C colorectal cancer.
It has been hypothesized that minichromosome maintenance (MCM) proteins, which are replicative control factors, can be used to detect tumor proliferation. The aim of the present study was to investigate the expression of MCM in colorectal cancer tissues and correlate it to clinical outcomes. The study included 145 patients with colorectal cancer who underwent curative surgery, from January 2002 until December 2004, at the Kurume University Hospital in Fukuoka, Japan. The median follow-up duration was 87 months. The expression of MCM7 in tissues was studied by immuno-histochemical staining. The labeling index (LI) of MCM7 was calculated by dividing the number of positively-stained cells by the total number of cells counted. We divided samples into two groups: positive (MCM7 LI 76% or higher) and negative (MCM7 LI less than 76%). In patients with Dukes A and B, there were no significant differences in either overall survival (OS) or recurrence-free survival (RFS) between patents with MCM7-positive and those with MCM7-negative disease. On the other hand, in patients with Dukes C, there was significantly worse OS and RFS for patients with MCM7-positive compared to those with MCM7-negative disease. We found that the expression of MCM7 is an independent risk factor for RFS in patients with Dukes C colorectal cancer. Further studies are required to investigate the validity of MCM7 protein expression for its potential clinical use in colorectal cancer therapy and prognosis.
- 1 August 2014
- Vol. 34 (8) , 4569-75
Minichromosome maintenance protein 7 is a risk factor for recurrence in patients with Dukes C colorectal cancer.
It has been hypothesized that minichromosome maintenance (MCM) proteins, which are replicative control factors, can be used to detect tumor proliferation. The aim of the present study was to investigate the expression of MCM in colorectal cancer tissues and correlate it to clinical outcomes. The study included 145 patients with colorectal cancer who underwent curative surgery, from January 2002 until December 2004, at the Kurume University Hospital in Fukuoka, Japan. The median follow-up duration was 87 months. The expression of MCM7 in tissues was studied by immuno-histochemical staining. The labeling index (LI) of MCM7 was calculated by dividing the number of positively-stained cells by the total number of cells counted. We divided samples into two groups: positive (MCM7 LI 76% or higher) and negative (MCM7 LI less than 76%). In patients with Dukes A and B, there were no significant differences in either overall survival (OS) or recurrence-free survival (RFS) between patents with MCM7-positive and those with MCM7-negative disease. On the other hand, in patients with Dukes C, there was significantly worse OS and RFS for patients with MCM7-positive compared to those with MCM7-negative disease. We found that the expression of MCM7 is an independent risk factor for RFS in patients with Dukes C colorectal cancer. Further studies are required to investigate the validity of MCM7 protein expression for its potential clinical use in colorectal cancer therapy and prognosis.
- 1 July 2013
- Vol. 33 (7) , 2941-7
Expression of monocarboxylate transporter (MCT)-4 in colorectal cancer and its role: MCT4 contributes to the growth of colorectal cancer with vascular endothelial growth factor.
In tumor cells, monocarboxylate transporter (MCT)-4 regulates the excretion of lactate produced by glycolysis from the cell. MCT4 has also been reported to be involved in tumor growth and infiltration. Similarly, vascular endothelial growth factor (VEGF) is known to be involved in the growth, infiltration, and metastasis of tumors. In this study, we clinically evaluated the relationship between MCT4 and VEGF in colorectal cancer. A prospective study was conducted in 210 patients with colorectal cancer who underwent surgical treatment. The clinicopathological data were correlated with the expression of MCT4 and VEGF obtained from immunohistochemical analysis. MCT4 and VEGF were expressed in tumors of 102 (49%) and 129 (61%) patients, respectively. A maximum tumor diameter of 45 mm or more (p<0.0001) and a tumor invasion depth of T1 or less (p<0.0119) were factors independently correlated with the expression of MCT4 and VEGF, respectively. The tumor size was significantly smaller (p=0.0031), and the disease was significantly less advanced (p=0.0017), in MCT4-negative/VEGF-positive than MCT4-positive/VEGF-negative cases. We suspect that in colorectal cancer, VEGF is involved in the early stages of tumor growth and MCT4 expression appears as the tumor enlarges and contributes to its further infiltration and growth.
- 1 July 2013
- Vol. 33 (7) , 2941-7
Expression of monocarboxylate transporter (MCT)-4 in colorectal cancer and its role: MCT4 contributes to the growth of colorectal cancer with vascular endothelial growth factor.
In tumor cells, monocarboxylate transporter (MCT)-4 regulates the excretion of lactate produced by glycolysis from the cell. MCT4 has also been reported to be involved in tumor growth and infiltration. Similarly, vascular endothelial growth factor (VEGF) is known to be involved in the growth, infiltration, and metastasis of tumors. In this study, we clinically evaluated the relationship between MCT4 and VEGF in colorectal cancer. A prospective study was conducted in 210 patients with colorectal cancer who underwent surgical treatment. The clinicopathological data were correlated with the expression of MCT4 and VEGF obtained from immunohistochemical analysis. MCT4 and VEGF were expressed in tumors of 102 (49%) and 129 (61%) patients, respectively. A maximum tumor diameter of 45 mm or more (p<0.0001) and a tumor invasion depth of T1 or less (p<0.0119) were factors independently correlated with the expression of MCT4 and VEGF, respectively. The tumor size was significantly smaller (p=0.0031), and the disease was significantly less advanced (p=0.0017), in MCT4-negative/VEGF-positive than MCT4-positive/VEGF-negative cases. We suspect that in colorectal cancer, VEGF is involved in the early stages of tumor growth and MCT4 expression appears as the tumor enlarges and contributes to its further infiltration and growth.
- 1 July 2011
- Vol. 31 (7) , 2517-25
Decreased expression of claudin-1 in rectal cancer: a factor for recurrence and poor prognosis.
To investigate the potential involvement of claudin-1 (CL-1) in the tumorigenesis of rectal cancer by analyzing the correlation between CL-1 expression, clinicopathological factors and prognosis. Rectal cancer tissue specimens from 306 patients that had undergone surgical treatment were evaluated using immunohistochemical analysis for expression of CL-1 and correlated with clinicopathological factors. A reduced expression of CL-1 (less than 30% of tumor cells strongly, positively stained) correlated significantly with poor prognosis in stage II and III rectal cancer. Moreover, the expression levels of CL-1 correlated significantly with tumor differentiation and perineural invasion (p=0.037 and 0.009, respectively). However, no significant differences were detected between the expression levels of CL-1 and other clinicopathological factors. Loss of claudin-1 expression is a strong predictor of disease recurrence and poor patient survival in stage II and III rectal cancer.
- 1 July 2011
- Vol. 31 (7) , 2517-25
Decreased expression of claudin-1 in rectal cancer: a factor for recurrence and poor prognosis.
To investigate the potential involvement of claudin-1 (CL-1) in the tumorigenesis of rectal cancer by analyzing the correlation between CL-1 expression, clinicopathological factors and prognosis. Rectal cancer tissue specimens from 306 patients that had undergone surgical treatment were evaluated using immunohistochemical analysis for expression of CL-1 and correlated with clinicopathological factors. A reduced expression of CL-1 (less than 30% of tumor cells strongly, positively stained) correlated significantly with poor prognosis in stage II and III rectal cancer. Moreover, the expression levels of CL-1 correlated significantly with tumor differentiation and perineural invasion (p=0.037 and 0.009, respectively). However, no significant differences were detected between the expression levels of CL-1 and other clinicopathological factors. Loss of claudin-1 expression is a strong predictor of disease recurrence and poor patient survival in stage II and III rectal cancer.
- 1 July 2011
- Vol. 31 (7) , 2541-5
Expression of IGF-1 and IGF-1R and their relation to clinicopathological factors in colorectal cancer.
Expression of insulin-like growth factor-1 (IGF-1) and IGF-1 receptor (IGF-1R) has been shown to increase in colorectal cancer. We examined the correlation between expression of IGF-1 and IGF-1R and clinicopathological factors in colorectal cancer. A prospective study was conducted of 210 colorectal cancer patients that underwent resection from January 2002 to December 2004. The clinicopathological data was correlated to expression of IGF-1 and IGF-1R obtained from immunohistochemical analysis. Statistical analysis was carried using univariate and multivariate analysis. IGF1 and IGF-1R staining was positive in 169 (80%) and 139 (66%) cases, respectively. Univariate and multivariate analyses showed significant correlation between expression of IGF-1 and tumor size (p=0.0024), and depth of invasion (p=0.0147). While IGF-1R was significantly correlated to tumor size and depth of invasion in univariate analysis, only tumor size (p=0.0658) had a strong association in multivariate analysis. Expression of IGF-1 and IGF-1R seems to increase with tumor size in colorectal cancer.
- 1 July 2011
- Vol. 31 (7) , 2541-5
Expression of IGF-1 and IGF-1R and their relation to clinicopathological factors in colorectal cancer.
Expression of insulin-like growth factor-1 (IGF-1) and IGF-1 receptor (IGF-1R) has been shown to increase in colorectal cancer. We examined the correlation between expression of IGF-1 and IGF-1R and clinicopathological factors in colorectal cancer. A prospective study was conducted of 210 colorectal cancer patients that underwent resection from January 2002 to December 2004. The clinicopathological data was correlated to expression of IGF-1 and IGF-1R obtained from immunohistochemical analysis. Statistical analysis was carried using univariate and multivariate analysis. IGF1 and IGF-1R staining was positive in 169 (80%) and 139 (66%) cases, respectively. Univariate and multivariate analyses showed significant correlation between expression of IGF-1 and tumor size (p=0.0024), and depth of invasion (p=0.0147). While IGF-1R was significantly correlated to tumor size and depth of invasion in univariate analysis, only tumor size (p=0.0658) had a strong association in multivariate analysis. Expression of IGF-1 and IGF-1R seems to increase with tumor size in colorectal cancer.
- 1 July 2011
- Vol. 31 (7) , 2547-52
Relationship between ulcerative colitis patients treated with leukocytapheresis and ulcerative colitis-associated colorectal cancer.
Leukocytapheresis (LCAP) is a recent modality for treatment of patients with ulcerative colitis (UC). This study aimed to assess whether LCAP changed the development of colorectal cancer (CRC) in patients with UC. A total of 42 patients with UC underwent surgical treatment from January 2001 until October 2010 at Kurume University Hospital. The patient details, preoperative therapy, operative indication and complications were obtained from our prospective database. Univariate, multivariate analysis and tree model were used for statistical analysis. In patients who received LCAP before surgery, CRC was significantly less frequent (p=0.0321). CRC incidence following LCAP increased when the disease period from diagnosis of UC exceeded 133 months. Multivariate analysis showed that the odds for undergoing LCAP were significantly higher (p=0.0305) in those cases with a total dose of steroid more than 2.57 g. LCAP may suppress CRC in UC patients.
- 1 July 2011
- Vol. 31 (7) , 2547-52
Relationship between ulcerative colitis patients treated with leukocytapheresis and ulcerative colitis-associated colorectal cancer.
Leukocytapheresis (LCAP) is a recent modality for treatment of patients with ulcerative colitis (UC). This study aimed to assess whether LCAP changed the development of colorectal cancer (CRC) in patients with UC. A total of 42 patients with UC underwent surgical treatment from January 2001 until October 2010 at Kurume University Hospital. The patient details, preoperative therapy, operative indication and complications were obtained from our prospective database. Univariate, multivariate analysis and tree model were used for statistical analysis. In patients who received LCAP before surgery, CRC was significantly less frequent (p=0.0321). CRC incidence following LCAP increased when the disease period from diagnosis of UC exceeded 133 months. Multivariate analysis showed that the odds for undergoing LCAP were significantly higher (p=0.0305) in those cases with a total dose of steroid more than 2.57 g. LCAP may suppress CRC in UC patients.
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
The Expression of Claudin-1 is an Effective Indicator of Recurrence and Prognosis in Stage II and Stage III Rectal Cancer
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
The Expression of Claudin-1 is an Effective Indicator of Recurrence and Prognosis in Stage II and Stage III Rectal Cancer